 Alzamend Neuro Inc NASDAQ: ALZN is surging higher Thursday after the company announced it received a written response to its meeting request relating to its Type B PreIND application from the FDA providing a path for Alzamends planned clinical development of AL002. AL002 is a patented method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine that seeks to restore the ability of a patients immunological system to combat Alzheimers. 